Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.10801PMID 12455059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural human anti-Galα(1,3)Gal antibodies react with human mucin peptides

  2004cited by this paper
• Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.

  2000cited by this paper
• Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n‐acetylgalactosamine (GalNAc) peptides

  2000cited by this paper
• Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti‐adhesion molecule

  2000cited by this paper
• Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

  2000cited by this paper
• Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors--relation to Lewis (a,b) histo-blood group phenotype.

  1999cited by this paper
• Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer

  1998cited by this paper
• Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women

  1998cited by this paper
• TNM Classification of Malignant Tumors

  1998cited by this paper
• Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides.

  1997cited by this paper
• Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.

  1994cited by this paper
• Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.

  1994cited by this paper
• Difference in sero‐diagnostic values among KL‐6‐associated mucins classified as cluster 9

  1994cited by this paper
• Human B-cell immune response to the polymorphic epithelial mucin.

  1993influential reference
• Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis.

  1993cited by this paper
• Mucin genes and the proteins they encode: structure, diversity, and regulation.

  1992influential reference
• Recognition of the Polypeptide Core of Mucin by Monoclonal Antibody MUSE11 against an Adenocarcinoma‐associated Antigen

  1990cited by this paper
• New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6.

  1989cited by this paper
• Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

  1989cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper

• Identification of B cell antigens in solid cancer: initial insights and functional implications

  2025cites this paper
• Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

  2025cites this paper
• A framework for the rational design of oncolytic viruses: A holistic perspective considering the tumour microenvironment.

  2025cites this paper
• Variables affecting CA15.3 tumor antigen expression and antibodies against it in female National Health and Nutritional Survey (NHANES) participants.

  2024cites this paper
• Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions

  2024cites this paper
• Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

  2024cites this paper
• Serum antibody screening using glycan arrays.

  2024cites this paper
• Incessant ovulation: a review of its importance in predicting cancer risk

  2023cites this paper
• Aspects of Phage-Based Vaccines for Protein and Epitope Immunization

  2023cites this paper
• Expression of CD 20 B-Lymphocyte in oral epithelial dysplasia and oral squamous cell carcinoma: A comparative immunohistochemistry study

  2023cites this paper
• Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study

  2022cites this paper
• Is it Time to Reconsider and Re-Stratergise B Lymphocyte Based Immunotherapy?

  2022cites this paper
• Sensitive and selective detection of Mucin1 in pancreatic cancer using hybridization chain reaction with the assistance of Fe3O4@polydopamine nanocomposites

  2022cites this paper
• Basic cancer immunology for radiation oncologists

  2022cites this paper
• Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants

  2022cites this paper
• B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma

  2022influential citation
• B cells in pancreatic cancer stroma

  2022cites this paper
• Liquid biopsy approach to pancreatic cancer

  2021cites this paper
• Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• The neglected brothers come of age: B cells and cancer.

  2021cites this paper
• Identi cation of a ve-gene prognostic signature related to B cells in ltration in pancreatic adenocarcinoma

  2021cites this paper
• B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients

  2021cites this paper
• Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate.

  2021cites this paper
• IL-36β promotes anti-tumor effects in CD8+ T cells by downregulating micro-RNA let-7c-5p

  2021cites this paper
• Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis

  2021cites this paper
• Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies

  2021cites this paper
• B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies

  2020cites this paper
• B cells and cancer: To B or not to B?

  2020cites this paper
• B cells, plasma cells and antibody repertoires in the tumour microenvironment

  2020cites this paper
• Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

  2020cites this paper
• Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study

  2020cites this paper
• Computational Modeling Of Mucin 1 (Muc1) Peptide And Anti-Muc1 Aptamer Binding

  2020cites this paper
• Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation

  2020cites this paper
• A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients

  2019cites this paper
• Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-Like Particles.

  2019cites this paper
• Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.

  2019cites this paper
• Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells

  2019cites this paper
• Autoantibody-targeted TAAs in pancreatic cancer: A comprehensive analysis.

  2019cites this paper
• Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches.

  2019cites this paper
• Multiplexed Autoantibody Signature for Serological Detection of Canine Mammary Tumours

  2018cites this paper
• MUC1 and Cancer Immunotherapy

  2018cites this paper
• Fumarate hydratase-specific T cell response in Chinese patients with autoimmune hepatitis.

  2018cites this paper
• Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas

  2018cites this paper
• Synthetic MUC1 Antitumor Vaccine with Incorporated 2,3‐Sialyl‐T Carbohydrate Antigen Inducing Strong Immune Responses with Isotype Specificity

  2018cites this paper
• Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.

  2018cites this paper
• Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.

  2018cites this paper
• Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities

  2018cites this paper
• The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer.

  2017cites this paper
• The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours.

  2017cites this paper
• Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.

  2017cites this paper
• Valency and density matter: Deciphering impacts of immunogen structures on immune responses against a tumor associated carbohydrate antigen using synthetic glycopolymers.

  2016cites this paper
• Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models

  2016cites this paper
• Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas

  2016cites this paper
• One Step Assembly of Thin Films of Carbon Nanotubes on Screen Printed Interface for Electrochemical Aptasensing of Breast Cancer Biomarker

  2016cites this paper
• A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection

  2016influential citation
• Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma

  2016cites this paper
• Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses.

  2016cites this paper
• The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy.

  2016cites this paper
• Immunotherapy of Pancreatic Cancer

  2015cites this paper
• SECRETORY EXPRESSION OF CA15-3 LIKE RECOMBINANT ANTIGEN IN MAMMALIAN CELLS

  2015cites this paper
• Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies

  2015cites this paper
• Immune Therapy in Pancreatic Cancer: Now and the Future?

  2015cites this paper
• Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.

  2015cites this paper
• Allogeneic IgG combined with dendritic cell stimuli induces anti-tumor T cell immunity

  2015cites this paper
• Molecular Dynamics Simulation Analysis of Anti-MUC1 Aptamer and Mucin 1 Peptide Binding.

  2015cites this paper
• Serum Anti-60S Ribosomal Protein L29 Antibody as a Novel Prognostic Marker for Unresectable Pancreatic Cancer

  2015cites this paper
• Vaccine Therapy for Pancreatic Cancer: As a Novel Therapeutic Approach?

  2014cites this paper
• Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy

  2014cites this paper
• Higher levels of antibodies to the tumour‐associated antigen cyclin B1 in cancer‐free individuals than in patients with breast cancer

  2014cites this paper
• Vaccine Therapy for Pancreatic Cancer: A Battle against Deadly Cancer

  2014cites this paper
• Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

  2014cites this paper
• Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.

  2014cites this paper
• Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells

  2014cites this paper
• Regulation by IL-10 of innate immune responses to MUC1 as a self-antigen in MUC1 transgenic mice

  2014cites this paper
• MUC1 immunotherapy is here to stay

  2013cites this paper
• The effects of host response and vaccine design on early signaling profiles of MUC1-specific T cells

  2013cites this paper
• Cancer-associated autoantibodies to MUC1 and MUC4—A blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening

  2013cites this paper
• The Relation of the Level of Serum Anti-TF, -Tn and -Alpha-Gal IgG to Survival in Gastrointestinal Cancer Patients

  2013cites this paper
• Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas

  2013cites this paper
• Exposure to Abnormal Self Antigens During Non-Malignant Inflammatory Events Provides Immunological Defense Against Tumors

  2013cites this paper
• What Is Recent in Pancreatic Cancer Immunotherapy?

  2012cites this paper
• Pancreatic Ductal Adenocarcinoma

  2012cites this paper
• Local Effects of Regulatory T Cells in MUC1 Transgenic Mice Potentiate Growth of MUC1 Expressing Tumor Cells In Vivo

  2012cites this paper
• Early diagnosis of pancreatic cancer: challenges and new developments.

  2012cites this paper
• The secret ally: immunostimulation by anticancer drugs

  2012cites this paper
• Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case–control study

  2012cites this paper
• Shifting the Paradigm in Radiation Safety

  2012cites this paper
• Immunodiagnostic Value of Combined Detection of Autoantibodies to Tumor‐associated Antigens as Biomarkers in Pancreatic Cancer

  2012cites this paper
• Mucins Differently Expressed in Various Ampullary Adenocarcinomas

  2011cites this paper
• Natural and Induced Humoral Responses to MUC1

  2011cites this paper
• Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer

  2011cites this paper
• Clinical trials of vaccines for immunotherapy in pancreatic cancer

  2011cites this paper
• Detection of D‐3‐phosphoglycerate dehydrogenase autoantibodies in patients with autoimmune hepatitis: Clinical significance evaluation

  2011cites this paper
• Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells.

  2011cites this paper
• Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies.

  2011cites this paper
• Autoantibodies in cancer: prognostic biomarkers and immune activation

  2011cites this paper
• Potential targets for pancreatic cancer immunotherapeutics.

  2011cites this paper
• Bioinformatics Analysis of Humoral Immune Response and Protein Microarray for Biomarker Discovery.

  2011cites this paper
• Molecular pathology of early pancreatic cancer

  2011cites this paper
• Detection of Circulating Anti-Mucin 1 (MUC1) Antibodies in Breast Tumor Patients by Indirect Enzyme-Linked Immunosorbent Assay Using a Recombinant MUC1 Protein Containing Six Tandem Repeats and Expressed in Escherichia coli

  2010cites this paper